Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy

Figure 1

Mass cytometry identification of cell activation and signaling signatures in a rheumatoid arthritis patient treated with tumor necrosis factor-α inhibitor. Whole blood was obtained from a rheumatoid arthritis (RA) patient with a responsive clinical outcome (American College of Rheumatology criteria ACR70) prior to and 1 month following the first application of tumor necrosis factor (TNF)-α inhibitor (TNFi) therapy. A healthy donor was used as a control. Whole blood cells were stimulated in vitro with 100 ng/ml TNF-α for 15 minutes at 37°C. Unstimulated cells from the same patient were used as a control. Cells were stained with a panel of 19 metal-tagged antibodies specific to cell surface and intracellular molecules and analyzed by CyTOF. SPADE (spanning-tree progression analysis of density normalized events) was used to cluster cells based on expression of cell surface lineage markers. SPADE analyses shows the level of p38 phosphorylation across annotated cell subsets in unstimulated (top panel) and in vitro TNF-α stimulated (bottom panel) cells in healthy donor (left), and RA patient prior to (middle) and 1 month following TNFi treatment (right). Each circular node represents a phenotypically similar population of white blood cells, with the relationship between nodes reflecting the most similar phenotypes to adjacent nodes. The node size represents frequency of that cell population and the node color displays the signal intensity of phosphorylated p38 expression according to the scale. SPADE trees were generated in Cytobank [50]. NK, natural killer; rTNF, recombinant TNF.

Back to article page